Research graph
References from Reply to Martorell Calatayud et al., “Cost-Consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-Severe Hidradenitis Suppurativa”. Local targets link to admitted publications; unresolved targets remain external evidence.
Cost-consequence Analysis of Secukinumab vs Adalimumab in Moderate-to-severe Hidradenitis Suppurativa
2025 · External reference
Two phase 3 trials of adalimumab for hidradenitis suppurativa
10.1056/nejmoa1504370 · 2016 · External reference
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE)
10.1016/s0140-6736(23)00022-3 · 2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
